AbbVie will be gaining rights to IGI Therapeutics’ lead candidate for oncology and autoimmune diseases in an exclusive ...

Vertex Pharmaceuticals’ triple combination cystic fibrosis (CF) therapy has been recommended by the National Institute for ...

The phase 3 BaxHTN trial has been evaluating two doses of the drug in patients with uncontrolled hypertension being treated ...

Innovative Trials, an internationally renowned clinical trials patient recruitment company based in the UK, has today ...

Kate Shaw, founder and CEO of Innovative Trials, has responded to data that shows the UK has far fewer women-only clinical ...

The US Food and Drug Administration (FDA) has announced the publication of more than 200 complete response letters (CRLs), ...

Merck & Co – known as MSD outside of the US and Canada – has announced that it will be expanding its respiratory diseases ...

The global communications group will unite six agencies under one roof in a purpose-built, hybrid workspace at the heart of ...

The European Commission (EC) has approved Biocon Biologics’ biosimilars referencing Amgen’s bone disease therapy denosumab.

The phase 3 FORTITUDE-101 trial, conducted with the support of Zai Lab, has been evaluating bemarituzumab plus mFOLFOX6 ...

While the year started out as cautiously optimistic, stemming from the peak of biotech initial public offering (IPO) activity ...

AstraZeneca (AZ) has announced that its Imfinzi (durvalumab)-based perioperative regimen has been approved by the European Commission (EC) to treat resectable muscle-invasive bladder cancer (MIBC).